Two Deals Beef Up AstraZeneca’s Rare Disease, Cancer Groups

AstraZeneca has strengthened its oncology and rare disease portfolios with two buy-outs totaling close to $3.5 billion, the company has reported.

The bigger deal, clinched with a $2 billion upfront payment and potential for $400 million in additional remuneration, brought oncology specialist Fusion Pharmaceuticals and its suite of tumor-targeting radioconjugate molecules into the fold.

In another $1.05 billion acquisition, AstraZeneca netted Amolyt Pharma and its lead compound, eneboparatide, a potential treatment for hypoparathyroidism.

To read the whole story, click here to subscribe.

Related Topics